Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 6
1981 2
1982 3
1983 7
1984 7
1985 7
1986 7
1987 7
1988 7
1989 10
1990 14
1991 4
1992 11
1993 9
1994 6
1995 6
1996 6
1997 6
1998 6
1999 6
2000 4
2001 4
2002 8
2003 8
2004 5
2005 6
2006 2
2007 9
2008 7
2009 8
2010 1
2011 6
2012 4
2013 7
2014 9
2015 7
2016 9
2017 6
2018 9
2019 12
2020 16
2021 11
2022 9
2023 4
2024 6
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

305 results

Results by year

Filters applied: . Clear all
Page 1
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: calabrese lh. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors).
Winthrop KL, Mariette X, Silva JT, Benamu E, Calabrese LH, Dumusc A, Smolen JS, Aguado JM, Fernández-Ruiz M. Winthrop KL, et al. Among authors: calabrese lh. Clin Microbiol Infect. 2018 Jun;24 Suppl 2:S21-S40. doi: 10.1016/j.cmi.2018.02.002. Epub 2018 Feb 12. Clin Microbiol Infect. 2018. PMID: 29447987 Free article. Review.
Drug-induced vasculitis.
Calabrese LH, Duna GF. Calabrese LH, et al. Curr Opin Rheumatol. 1996 Jan;8(1):34-40. doi: 10.1097/00002281-199601000-00006. Curr Opin Rheumatol. 1996. PMID: 8867537 Review.
Viral arthritis.
Calabrese LH, Naides SJ. Calabrese LH, et al. Infect Dis Clin North Am. 2005 Dec;19(4):963-80, x. doi: 10.1016/j.idc.2005.09.002. Infect Dis Clin North Am. 2005. PMID: 16297742 Review.
Infection and Malignancy in Rheumatic Diseases.
Winthrop KL, Calabrese LH. Winthrop KL, et al. Among authors: calabrese lh. Rheum Dis Clin North Am. 2017 Feb;43(1):xiii-xiv. doi: 10.1016/j.rdc.2016.10.001. Rheum Dis Clin North Am. 2017. PMID: 27890178 No abstract available.
Inclusion body myositis.
Calabrese LH, Chou SM. Calabrese LH, et al. Rheum Dis Clin North Am. 1994 Nov;20(4):955-72. Rheum Dis Clin North Am. 1994. PMID: 7855331 Review.
Mechanistic insights into bone remodelling dysregulation by human viral pathogens.
Caetano CCS, Azamor T, Meyer NM, Onwubueke C, Calabrese CM, Calabrese LH, Visperas A, Piuzzi NS, Husni ME, Foo SS, Chen W. Caetano CCS, et al. Among authors: calabrese lh. Nat Microbiol. 2024 Feb;9(2):322-335. doi: 10.1038/s41564-023-01586-6. Epub 2024 Feb 5. Nat Microbiol. 2024. PMID: 38316931 Free PMC article. Review.
305 results